Case Reports in Obstetrics and Gynecology
Volume 2016 (2016), Article ID 7041686, 4 pages
Marianna Politou,1 Serena Valsami,1 Irontianta Gkorezi-Ntavela,1 Vasilios Telonis,1 Efrosyni Merkouri,2 and Panagiotis Christopoulos3
1Blood Transfusion Department, Aretaieion Hospital, National and Kapodistrian Athens University Medical School, 11528 Athens, Greece
2Coagulation Laboratory, Iatriko Kentro Hospital, 11525 Athens, Greece
32nd Department of Obstetrics and Gynecology, Aretaieion Hospital, National and Kapodistrian Athens University Medical School, 11528 Athens, Greece
Essential thrombocytosis (ET) and FV Leiden heterozygosity represent an acquired and hereditable hypercoagulable state, respectively. An uncommon case of coexistence of ET and FV Leiden heterozygosity in a 36-year-old pregnant woman and her successful pregnancy outcome is described. She was considered to be at high risk of thrombosis during her pregnancy and she was treated with both prophylactic dose of LMWH and aspirin daily throughout her pregnancy and for a 6-week period postpartum. The efficacy of the anticoagulation treatment was monitored in various time points not only by measuring anti-Xa levels and D-Dimers but also with new coagulation methods such as rotation thromboelastometry and multiplate. Global assessment of coagulation using additional newer laboratory tests might prove useful in monitoring coagulation pregnancies at high risk for thrombosis.